The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Sacubitril/valsartan in primary care: the commissioner’s role

Sacubitril/valsartan in primary care: the commissioner’s role

Publication date: Monday, 24 October 2016
Contributor(s): Nigel Rowell

Commissioning is not so different from seeing patients. As a GP you listen, examine, draw up a diagnosis and plan treatment. In commissioning, the community served by the clinical commissioning group (CCG) is the ‘patient’. When considering the introduction of a new treatment for heart failure (HF) such as sacubitril/valsartan (Entresto), we must consider not only its acquisition costs but also its potential benefits in improving patients' symptoms and reducing expensive hospital admissions.

Sponsorship information:
his sponsored supplement was initiated and funded by Novartis. Novartis reviewed the supplement for technical accuracy and suitability within the ABPI Code of Practice. Final editorial control rests with the authors and editors.
Topics covered:
Category: Editorial
Edition: Volume 9 Number 1 Oct-Nov-Dec 2016
Contributor(s): Nigel Rowell

Article search and filter